Research and development daily Novartic's rare disease drug Branaplam has been awarded the title of orphan drug by the FDA.

2020.10.23 Research and Development NEWS FDA Approves Redsiway Treatment COVID-19; Takeda's "Aitibant" Listing Application To Be Included in Priority Review; Priut Pharmaceuticals Sulphur Teb Taling 4 generic listing applications were accepted; "cancer environmental immunotherapy" targeting TGF-β or a new dawn against cancer; Henri PD-1 joint Apatini III clinical approval... We focus on the latest developments in pharmaceutical research and development, to provide research and development personnel with timely and accurate information reference.
(click on the title, read the original article) The FDA approved Redsyvir's treatment COVID-1922, the FDA officially approved Gilead's Redsiway listing for the treatment of COVID-19 adults and pediatric patients over 12 years of age (weight ≥ 40 kg) who need hospitalization, becoming the first COVID-19 treatment to be officially approved by the FDA.
Novarda rare disease drug Branaplam was awarded the FDA's orphan drug title 21, Novardo announced that the U.S. FDA has awarded the drug Branaplam (LMI070) orphan drug for the treatment of Huntington's disease (HD), the company plans to start in 2021 in HD patients Branaplam's Phase IIb clinical trial.
The potential "best-in-class" therapy Oconway Bioco-Technology New Drug was approved for clinical CDE official website announced today, Ocon vision biology and Nicox jointly declared a new class of 1 drug NCX470 eye drops approved by clinical trials, intended to develop for the reduction of open-angle glare or high eye pressure patients with intra-eye pressure.
days guangshi biological anti-tumor class 1 new drugs were approved clinically today, CDE official website announced that Tianguang real biology submitted a new class of drugs MIL93 injection to obtain a clinical implied license, adaptation for local late stage or metastasis solid tumor.
MIL93 is a recombinant humanized monoclonal antibody targeting Claudin 18.2, which is intended to be developed for the treatment of Cludin 18.2-positive stomach and pancreatic cancer, according to the prospectus.
's "Aitibant" listing application is to be included in the priority review today, CDE's latest public announcement, Takeda's acetic acid Aitibant injection listing application is to be included in the priority review.
was developed by Takeda's Shire company to treat acute episodes of hereditary angioedema.
Priut Pharmaceuticals Sulphate Tebutalin 4 class imitation listing application was accepted 22, CDE official website data show that four Trump Reit pharmaceutical industry's sulfate tebutalin atomized inhalation solution 4 type imitation listing application was accepted, the domestic Tebutalin inhaler leader for AstraZenecon.
Boan Biodeshudon Anti-Injections were approved for clinical conduct in Europe today, Greenlee Pharmaceutical Group announced that its subsidiary Boan Bio-autonomously developed recombinant anti-RANKL all-human monoclonal antibody injections (Deshuan anti-injections, LY06006 / LY01011) have been approved by the German Federal Ministry of Health Vaccines and the Federal Institute of Biomedical Sciences to initiate clinical trials.
Hengrui PD-1 joint Apatini III clinical approval for HCC postoperative ancillary treatment 23, Hengrui Pharmaceuticals announced that the company recently received NMPA "Drug Clinical Trial Approval Notice" to approve its PD-1 single anti-carelli pearl monoantigeno apatini for liver cell carcinoma (HCC) root surgery or after ablation associated with high risk of recurrence of complementary treatment.
will conduct this Phase III clinical trial in the near future.
Qilu first injection supplement application evaluation 41 product leading industry 22, NMPA released the latest batch of drug approval information, there are two injections of consistent evaluation of supplementary applications approved, become the 21st CDE on injection consistency evaluation of supplementary information related matters issued after the release of the first evaluation of injections, no doubt for the industry a strong injection.
latest research: Nature breakthrough! Two recent articles in the journal Cancer Environmental Immunotherapy, or New Dawn Nature, which targets TGF-β, point out that "cancer environmental immunotherapy" and an antibody-based drug, 4T-Trap, have successfully curbed cancer progress in mice.
researchers believe that pharmacological suppression of TGF-β signals in auxiliary T-cells may be a new type of cancer therapy and a powerful complement to existing cancer immunotherapy.
.